L Taillandier
Overview
Explore the profile of L Taillandier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dufour J, Choquet S, Hoang-Xuan K, Schmitt A, Ahle G, Houot R, et al.
Ann Hematol
. 2023 Mar;
102(5):1159-1169.
PMID: 36991231
Primary central nervous system lymphomas (PCNSLs) classically remain confined within the CNS throughout their evolution for unknown reasons. Our objective was to analyse the rare extracerebral relapses of PCNSL in...
2.
Demogeot N, Salleron J, Rech F, Taillandier L, Royer P, G Vogin
Radiat Oncol
. 2022 Dec;
17(1):201.
PMID: 36474245
Background: The prognosis of recurrent glioblastoma (GBM) is poor, with limited options of palliative localized or systemic treatments. Survival can be improved by a second localized treatment; however, it is...
3.
Hernandez-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, et al.
Ann Oncol
. 2022 Nov;
34(2):186-199.
PMID: 36402300
Background: Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B-cell lymphoma presenting with variable response rates probably to underlying molecular heterogeneity. Patients And...
4.
Morisse M, Etienne-Selloum N, Bello-Roufai D, Blonski M, Taillandier L, Lorgis V, et al.
J Neurooncol
. 2019 Jul;
144(2):419-426.
PMID: 31325146
Purpose: Recurrence of glioblastoma (GB) occurs in most patients after standard concomitant temozolomide-based radiochemotherapy (CTRC). Bevacizumab (BV), an anti-VEGF antibody, has an effect on progression-free survival (PFS) but not on...
5.
Royer P, Salleron J, G Vogin , Taillandier L, Clement-Duchene C, Klein O, et al.
Cancer Radiother
. 2017 Jul;
21(8):731-740.
PMID: 28711413
Purpose: To study overall survival, risk of neurological death, local recurrence and development of new brain metastasis in patients treated for brain oligometastases with hypofractionated stereotactic radiotherapy with CyberKnife, according...
6.
Zouaoui S, Darlix A, Rigau V, Mathieu-Daude H, Bauchet F, Bessaoud F, et al.
Neurochirurgie
. 2015 Jun;
64(1):15-21.
PMID: 26073920
Purpose: This work describes the clinical epidemiology and pathology for patients undergoing surgery for newly diagnosed meningiomas in France between 2006 and 2010. Methods: The methodology is based on a...
7.
Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, et al.
J Neurol
. 2015 May;
262(7):1637-45.
PMID: 25929666
Isolated tumefactive demyelinating lesion (TDL) is a rare disease and a challenging entity especially for the differential diagnosis, biopsy indications, and therapeutic decisions. Long-term evolution is not well known. The...
8.
Taillandier L, Le Rhun E, Metellus P, Mornex F, Mazeron J
Cancer Radiother
. 2015 Feb;
19(1):1-2.
PMID: 25662598
No abstract available.
9.
Le Rhun E, Taillibert S, Blonski M, Jouniaux Delbez N, Delgadillo D, Taillia H, et al.
Cancer Radiother
. 2015 Feb;
19(1):55-60.
PMID: 25640218
Brain metastases impact on the survival of the patients, but on their quality of life as well. The objective of the management of these patients is then double. Currently, due...
10.
Karayan-Tapon L, Cortes U, Rivet P, Jermidi C, Vassal G, Wager M, et al.
Eur J Cancer
. 2014 Jul;
50(13):2364-6.
PMID: 24999209
No abstract available.